An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 779-790

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; FEMALE; GENE; GENE MUTATION; HUMAN; IGHV GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TP53 GENE; VALIDATION STUDY; CLINICAL TRIAL (TOPIC); LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84966746552     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30029-8     Document Type: Article

References (34)

1. 1 Rai, KR, Sawitsky, A, Cronkite, EP, Chanana, AD, Levy, RN, Pasternack, BS, Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975), 219–234.
2. 2 Binet, JL, Auquier, A, Dighiero, G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981), 198–206.
3. 3 Landau, DA, Tausch, E, Taylor-Weiner, AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526 (2015), 525–530.
4. 4 Puente, XS, Bea, S, Valdes-Mas, R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526 (2015), 519–524.
5. 5 Döhner, H, Stilgenbauer, S, Benner, A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000), 1910–1916.
6. 6 Hallek, M, Fischer, K, Fingerle-Rowson, G, et al. on behalf of an international group of investigators, the German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376 (2010), 1164–1174.
7. 7 Zenz, T, Eichhorst, B, Busch, R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28 (2010), 4473–4479.
8. 8 Damle, RN, Wasil, T, Fais, F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999), 1840–1847.
9. 9 Hamblin, TJ, Davis, Z, Gardiner, A, Oscier, DG, Stevenson, FK, Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999), 1848–1854.
10. 10 Crespo, M, Bosch, F, Villamor, N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003), 1764–1775.
11. 11 Rassenti, LZ, Jain, S, Keating, MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112 (2008), 1923–1930.
12. 2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22 (1996), 439–447.
13. 13 Puente, XS, Pinyol, M, Quesada, V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475 (2011), 101–105.
14. 14 Quesada, V, Conde, L, Villamor, N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44 (2012), 47–52.
15. 15 Lepretre, S, Aurran, T, Mahe, B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119 (2012), 5104–5110.
16. 16 Bergmann, MA, Busch, R, Eichhorst, B, et al. Overall survival in early stage chronic lymphocytic leukemia patients with treatment indication due to disease progression: follow-up data of The CLL1 trial of the German CLL Study Group (GCLLSG). Blood, 122, 2013, 4127.
17. 17 Eichhorst, BF, Busch, R, Hopfinger, G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006), 885–891.
18. 18 Eichhorst, BF, Busch, R, Stilgenbauer, S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114 (2009), 3382–3391.
19. 19 Robak, T, Jamroziak, K, Gora-Tybor, J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 28 (2010), 1863–1869.
20. 20 Catovsky, D, Richards, S, Matutes, E, et al. on behalf of the UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group, NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (2007), 230–239.
21. 21 Flinn, IW, Neuberg, DS, Grever, MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25 (2007), 793–798.
22. 22 Cheson, BD, Bennett, JM, Grever, M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996), 4990–4997.
23. 23 Mansouri, L, Cahill, N, Gunnarsson, R, et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 27 (2013), 512–514.
24. 24 Little, RJA, A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc 83 (1988), 1198–1202.
25. 25 Hallek, M, Cheson, BD, Catovsky, D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (2008), 5446–5456.
26. 26 Byrd, JC, Furman, RR, Coutre, SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013), 32–42.
27. 27 Roberts, AW, Davids, MS, Pagel, JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374 (2016), 311–322.
28. 28 Wierda, WG, O'Brien, S, Wang, X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109 (2007), 4679–4685.
29. 29 Pflug, N, Bahlo, J, Shanafelt, TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124 (2014), 49–62.
30. 30 Tam, CS, Seymour, JF, A new prognostic score for CLL. Blood 124 (2014), 1–2.
31. 31 Rossi, D, Rasi, S, Spina, V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121 (2013), 1403–1412.
32. 32 Wang, L, Lawrence, MS, Wan, Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365 (2011), 2497–2506.
33. 33 Byrd, JC, Furman, RR, Coutre, SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125 (2015), 2497–2506.
34. 34 Howlader, N, Noone, AM, Krapcho, M, et al. (eds.) SEER clinical statistics review, 1975–2007, 2010, National Cancer Institute, Bethesda, MD.